Follow
Tumor heterogeneity
Tumor heterogeneity describes differences between tumors. Tumor heterogeneity can refer to differences between (1) tumors in different patients, (2) cancer cells in an individual patient's tumor, or (3) a primary and metastatic tumor. Understanding the heterogeneity of a tumor can facilitate diagnosis and treatment.
MAY 19, 2020 | 1:15 PM
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...
MAY 19, 2020 | 11:45 AM
Pancreatic ductal adenocarcinoma (PDAC) remains a treatment-refractory disease and existing molecular subtypes do not inform clinical decisions. Previously-identified bulk transcriptomic sub...
MAY 14, 2020 | 3:00 PM
Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfD...
MAY 14, 2020 | 3:00 PM
Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfD...
APR 29, 2020 | 8:00 AM
Date: April 29, 2020 Time: 8:00AM PDT, 11:00AM EDT Single cell genomics and other next generation sequencing applications depend strongly on adequate upstream sample preparation. Results can...
APR 28, 2020 | 10:00 AM
DATE: April 28, 2020 TIME: 10:00am PT All cells release extracellular vesicles (EVs) that can carry molecular cargo to other cells to affect their function. EVs are promising as potential bi...
FEB 26, 2020 | 12:00 PM
Digital spatial profiling (DSP) on the NanoString GeoMx platform enables high plex molecular profiling of clinical tissue samples. This new profiling strategy enables deep insights into the...
FEB 26, 2020 | 7:30 AM
Recent advances in DNA sequencing and omics-based capabilities are revealing incredible therapeutic opportunities and quickly transforming drug discovery. Molecularly targeted drugs aim to e...
JAN 01, 2020 | 6:00 AM
“The poor translatability of early-stage preclinical models is a major setback in oncology drug development. Immortalized cell lines, that are extensively used in drug screens, undergo...
NOV 21, 2019 | 8:00 AM
DATE: November 21, 2019TIME: 8:00am PSTA complex interaction among heterogenous immune and tumor cells within the tumorous tissue not only influences tumor progression, but can also sha...
NOV 12, 2019 | 10:00 AM
DATE: November 12, 2019TIME: 10:00am PSTDirect measurement of copy number by droplet-based shallow sequencing of genomic DNA has the potential to provide new insights into tumor heterog...
SEP 17, 2019 | 9:00 AM
DATE: September 17, 2019TIME: 9:00am PTSpatial Transcriptomics (ST) technology reveals gene expression from up to one thousand spots across a tissue section. In this webinar, Dr. H...
JUN 20, 2019 | 1:30 PM
Tumor heterogeneity is a hallmark of cancer and can have significant impact on identifying drivers, including those that may be therapeutically relevant. Although, the traditional sequencing...
